Development and validation of multiple machine learning algorithms for differentiating primary central nervous system lymphoma from adult-type diffuse glioma: an interpretable and multicenter study

开发和验证多种机器学习算法以区分原发性中枢神经系统淋巴瘤和成人型弥漫性胶质瘤:一项可解释的多中心研究

阅读:1

Abstract

BACKGROUND: Preoperative differentiation of primary central nervous system lymphoma (PCNSL) from adult-type diffuse glioma(ADG) is important to guide neurosurgical decision-making.To develop and validate a MRI-based interpretable radiomic-clinical(Rad-Clinic) fusion model to differentiate PCNSL from ADG by seven machine learning algorithms. METHODS: In this retrospective study, we recruited 165 patients who underwent preoperative conventional MRI(CET1WI, FLAIR, DWI, ADC) with PCNSL and ADG from two institutions (115 in the training cohort and 50 in the external validation cohort). we selected seven machine learning algorithms to construct a framework incorporating radiomic features and clinical parameters. SHapley Additive exPlanations (SHAP) values elucidated feature contributions, and a radiomic nomogram was developed for clinical translation. RESULTS: The CET1WI+DWI+FLAIR fusion model exhibited optimal performance among all the single-sequence and multi-sequence radiomic models, and the AUC for external validation cohort were 0.871. But the Rad-Clinic fusion model performed well in differentiating PCNSL from ADG, and the AUC for the training and external validation cohort were 0.973 and 0.940, outperforming radiomic model and clinical model.SHAP summary plot illustrated the feature's value affected the feature'simpact attributed to the Rad-Clinic fusion model.The nomogram demonstrated clinical interpretability through visualised risk stratification. CONCLUSION: An interpretable Rad-Clinic fusion model enables accurate preoperative to differentiate PCNSL from ADG, and may assist improve clinical decision-making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。